Journey Medical (DERM) Projected to Post Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is projected to announce its Q1 2025 earnings results after the market closes on Wednesday, May 14th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $12.05 million for the quarter.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.30. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%. The firm had revenue of $14.30 million during the quarter, compared to analysts’ expectations of $14.21 million. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Journey Medical Price Performance

DERM opened at $6.83 on Tuesday. The company has a fifty day moving average price of $6.32 and a two-hundred day moving average price of $5.40. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a 52 week low of $3.20 and a 52 week high of $7.84. The firm has a market capitalization of $157.80 million, a PE ratio of -7.27 and a beta of 0.86.

Insiders Place Their Bets

In other news, CEO Claude Maraoui sold 18,147 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total value of $93,094.11. Following the sale, the chief executive officer now directly owns 2,092,874 shares of the company’s stock, valued at approximately $10,736,443.62. This represents a 0.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 113,522 shares of company stock valued at $589,229 in the last three months. 13.16% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DERM. Alliance Global Partners reissued a “buy” rating on shares of Journey Medical in a report on Thursday, March 27th. Industrial Alliance Securities set a $10.50 price target on shares of Journey Medical in a report on Thursday, March 27th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $9.88.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.